As 96% of patients with primary glioblastoma contain wt IDH1 (as compared to only 27% of secondary glioblastoma) [56], our study is only relevant to potential IL-11Rα-enhanced survival advantages in the primary glioblastoma context. The gene discussed is IDH1; the disease is glioblastoma.